Order-Disorder Transitions Govern Kinetic Cooperativity and Allostery of Monomeric Human Glucokinase

PLoS Biology

Volumn 10, Issue 12, 2012, Pages

  Larion, Mioara ^a   Salinas, Roberto Kopke ^a,b,c   Bruschweiler Li, Lei ^a,c   Miller, Brian G ^a   Brüschweiler, Rafael ^a,c  

^a FLORIDA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOKINASE; GLUCOSE; ISOLEUCINE; METHYL GROUP; MONOMER; TRYPTOPHAN;

ALLOSTERISM; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME KINETICS; HUMAN; MOLECULAR MECHANICS; NUCLEAR MAGNETIC RESONANCE; PHASE TRANSITION; PROTEIN CONFORMATION; PROTEIN DOMAIN;

ALLOSTERIC REGULATION; AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; CONGENITAL HYPERINSULINISM; ENZYME ACTIVATION; ENZYME STABILITY; GLUCOKINASE; GLUCOSE; HUMANS; ISOLEUCINE; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84871675389     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001452     Document Type: Article

References (60)

1. Bell GI, Polonsky KS, (2001) Diabetes mellitus and genetically programmed defects in β-cell function. Nature 414: 788-791.
2. Cornish-Bowden A, Cárdenas ML (2004) Glucokinase: a monomeric enzyme with positive cooperativity. In: Matschinsky FM, Magnuson MA, editors. Glucokinase and glycemic disease: from basics to novel therapeutics. Frontiers in Diabetes. Basel: Karger pp. 125-134.
3. Matschinsky FM, (1990) Glucokinase as glucose sensor and metabolic signal generator in pancreatic β-cells and hepatocytes. Diabetes 39: 647-652.
4. Meglasson MD, Matschinsky FM, (1984) New perspectives in pancreatic islet glucokinase. Am J Physiol Endocrinol Metab 246: E1-E13.
5. Al-Hasani H, Tschöp MH, Cushman SW, (2003) Two birds with one stone: novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism. Mol Interv 3: 367-374.
6. Vionnet N, Stoffel M, Takeda J, Yasuda K, Bell GI, et al. (1992) Nonsense mutation in the glucokinase gene causes early onset non-insulin-dependent diabetes mellitus. Nature 356: 721-722.
7. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, et al. (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338: 226-230.
8. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanné-Chantelot C, et al. (2009) Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30: 1512-1526.
9. Cuesta-Muñoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Näntö-Salonen K, et al. (2004) Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 53: 2164-2168.
10. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, et al. (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338: 226-230.
11. Golyn AL, (2003) Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 22: 353-362.
12. Glaser B, Thornton PS, Otonkoski T, Junien C, (2000) Genetics of neonatal hyperinsulinism. Arch Dis Child 82: 79-86.
13. Meissner T, Marquard J, Cobo-Vuilleumier N, Maringa M, Rodríguez-Bada P, et al. (2009) Diagnostic difficulties in glucokinase hyperinsulinism. Horm Metab Res 41: 320-326.
14. Christesen HBT, Tribble ND, Molven A, Siddiqui J, Sandal T, et al. (2008) Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol 159: 27-34.
15. Wabitsch M, Lahr G, Van de Bunt M, Marchant C, Lindner M, et al. (2007) Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabet Med 24: 1393-1399.
16. Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, et al. (2003) Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52: 2433-2440.
17. Davis EA, Cuesta-Munoz AL, Raoul M, Buettger C, Sweet I, et al. (1999) Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 42: 1175-1186.
18. Gloyn AL, Odili S, Buettger C, Njølstad PR, Shiota C, et al. (2004) Glucokinase and the regulation of blood sugar. A mathematical model predicts the threshold for glucose stimulated insulin release for GCK gene mutations that cause hyper- and hypoglycemia. In: Matschinsky FM, Magnuson MA, editors. Glucokinase and glycemic disease: from basics to novel therapeutics. Frontiers in Diabetes. Basel: Karger pp. 92-109.
19. Pal P, Miller BG, (2009) Activating mutations in the human glucokinase gene revealed by genetic selection. Biochemistry 48: 814-816.
20. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, et al. (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370-373.
21. Matschinsky FM, (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8: 399-416.
22. Wyman J, (1963) Allosteric effects in hemoglobin. Cold Spring Harb Symp Quant Biol 28: 483-489.
23. Kantrowitz ER, Lipscomb WN, (1988) Escherichia coli aspartate transcarbamylase: the relation between structure and function. Science 241: 669-674.
24. Monod J, Wyman J, Changeux J-P, (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12: 88-118.
25. Koshland DE Jr, Némethy G, Filmer D, (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5: 365-385.
26. Ainslie GR Jr, Shill JP, Neet KE, (1972) Transients and cooperativity. A slow transition model for relating transients and cooperative kinetics of enzymes. J Biol Chem 247: 7088-7096.
27. Richard J, Meunier J-C, Buc J, (1974) Regulatory behavior of monomeric enzymes. 1. The mnemonical enzyme concept. Eur J Biochem 49: 195-208.
28. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y, (2004) Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12: 429-438.
29. Liu S, Ammirati MJ, Song X, Knafels JD, Zhang J, et al. (2012) Insights into mechanism of glucokinase activation: observation of multiple distinct protein conformations. J Biol Chem 287: 13598-13610.
30. Neet KE, Keenan RP, Tippett PS, (1990) Observation of a kinetic slow transition in monomeric glucokinase. Biochemistry 29: 770-777.
31. Lin SX, Neet KE, (1990) Demonstration of a slow conformational change in liver glucokinase by fluorescence spectroscopy. J Biol Chem 265: 9670-9675.
32. Larion M, Salinas RK, Bruschweiler-Li L, Brüschweiler R, Miller BG, (2010) Direct evidence of conformational heterogeneity in human pancreatic glucokinase from high-resolution nuclear magnetic resonance. Biochemistry 49: 7969-7971.
33. Zelent B, Buettger C, Grimsby J, Sarabu R, Vanderkooi JM, et al. (2012) Thermal stability of glucokinase (GK) as influenced by the substrate glucose, an allosteric glucokinase activator drug (GKA) and the osmolytes glycerol and urea. Biochimica et Biophysica Acta 1824: 769-784.
34. Petit P, Antoine M, Ferry G, Boutin JA, Lagarde A, et al. (2011) The active conformation of human glucokinase is not altered by allosteric activators. Acta Cryst D67: 929-935.
35. Liu Q, Shen Y, Liu S, Weng J, Liu J, (2011) Crystal structure of E339K mutated human glucokinase reveals changes in the ATP binding site. FEBS Lett 585: 1175-1179.
36. Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, et al. (2009) Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 52: 6142-6152.
37. Nishimura T, Iino T, Mitsuya M, Bamba M, Watanabe H, et al. (2009) Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators. Bioorg Med Chem Lett 19: 1357-1360.
38. Mitsuya M, Kamata K, Bamba M, Watanabe H, Sasaki Y, et al. (2009) Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators. Bioorg Med Chem Lett 19: 2718-2721.
39. Tugarinov V, Kanelis V, Kay LE, (2006) Isotope labeling strategies for the study of high-molecular-weight proteins by solution NMR spectroscopy. Nat Protoc 1: 749-754.
40. Sprangers R, Kay LE, (2007) Quantitative dynamics and binding studies of the 20S proteasome by NMR. Nature 445: 618-622.
41. Muchmore DC, Mcintosh LP, Russell CB, Anderson DE, Dahlquist FW, (1989) Expression and nitrogen-15 labeling of proteins for nitrogen-15 Nuclear Magnetic Resonance. Method Enzymol 177: 44-73.
42. Wishart DS, Sykes BD, (1994) The 13C Chemical-Shift Index: a simple method for the identification of protein secondary structure using 13C chemical-shift data. J Biomol NMR 4: 171-180.
43. Hansen DF, Neudecker P, Kay LE, (2010) Determination of isoleucine side-chain conformations in ground and excited states of proteins from chemical shifts. J Am Chem Soc 133: 8272-8281.
44. Larion M, Miller BG, (2009) 23-residue C-terminal α-helix governs kinetic cooperativity in monomeric human glucokinase. Biochemistry 48: 6157-6165.
45. Heredia VV, Thomson J, Nettleton D, Sun S, (2006) Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis. Biochemistry 45: 7553-7562.
46. Kim YB, Kalinowski SS, Marcinkeviciene J, (2007) A pre-steady state analysis of ligand binding to human glucokinase: evidence for a preexisting equilibrium. Biochemistry 46: 1423-1431.
47. Antoine M, Boutin JA, Ferry G, (2009) Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states. Biochemistry 48: 5466-5482.
48. Larion M, Miller BG, (2010) Global fit analysis of glucose binding curves reveals a minimal model for kinetic cooperativity in human glucokinase. Biochemistry 49: 8902-8911.
49. Frieden C, (1970) Kinetic aspects of regulation of metabolic processes. The hysteretic enzyme concept. J Biol Chem 245: 5788-5799.
50. Bogatyreva NS, Osypov AA, Ivankov DN, (2009) KineticDB: a database of protein folding kinetics. Nucl Acids Res 37: D342-D346.
51. Dyson HJ, Wright PE, (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 6: 197-208.
52. Zambelli B, Cremades N, Neyroz P, Turano P, Uversky V, et al. (2012) Insights in the (un)structural organization of Bacillus pasteurii UreG, an intrinsically disordered GTPase enzyme. Mol BioSyst 8: 220-228.
53. Baltrusch S, Lenzen S, Okar DA, Lange AJ, Tiedge M, (2001) Characterization of glucokinase-binding protein epitopes by a phage-displayed peptide library: identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel interaction partner. J Biol Chem 276: 43915-43923.
54. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, et al. (2003) BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952-956.
55. van Schaftingen EF, Veiga da Cunha M (2004) Discovery and role of glucokinase regulatory protein. In: Matschinsky FM, Magnuson MA, editors. Glucokinase and glycemic disease: from basics to novel therapeutics. Frontiers in Diabetes. Basel: Karger. pp 125-134.
56. Rizzo MA, Piston DW, (2003) Regulation of β-cell glucokinase by S-nitrosylation and association with nitric oxide synthase. J Cell Biol 161: 243-248.
57. Bjorkhaug L, Molnes J, Søvik O, Njølstad PR, Flatmark T, et al. (2007) Allosteric activation of human glucokinase by free polyubiquitin chains and its ubiquitin-dependent cotranslational proteasomal degradation. J Biol Chem 282: 22757-22764.
58. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, et al. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6: 277-293.
59. Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, et al. (2005) The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59: 687-696.
60. Marsh JA, Singh VK, Jia Z, Forman-Kay JD, (2006) Sensitivity of secondary structure propensities to sequence differences between α- and γ-synuclein: implications for fibrillation. Proteins 15: 2795-2804.